HER2-TARGETED THERAPIES

Data from a single-institution study—presented during the Virtual 2020 ASCO Annual Meeting—suggests that HER2-Ile655 A˃G polymorphism is significantly associated with a higher risk of trastuzumab-induced cardiotoxicity. It was not, however, associated with disease-free or overall survival. The results also showed that diabetes and baseline high NT-proBNP levels may be predictive for the development of trastuzumab-induced cardiotoxicity.